Henlius and Sandoz Expand Biosimilars Framework in Deal Worth Up to $322 Million

Companies: Shanghai Henlius Biotech & Sandoz · Event Type: Multi-Asset Biosimilars Collaboration · Deal Value: Up to $322 Million (Initial Arrangements) · Assets: HLX05-N, HLX16, Belimumab Biosimilar, HLXTE-HAase1001 (Option) · Announcement Date: August 17, 2026 Summary Shanghai Henlius Biotech and Sandoz expanded their biosimilars relationship…